Key Takeaways:
UnitedHealth Group will cover Guardant Health Inc.'s Shield blood test for colorectal cancer screening, unlocking 100 million covered lives and making it the most broadly accessible blood-based CRC screening option in the US.
"Expanding Shield coverage through the nation's largest commercial health insurer to the 45-plus population marks a critical milestone in our commercial expansion," AmirAli Talasaz, co-chief executive officer at Guardant Health, said.
Shield detects DNA methylation alterations in cell-free DNA from a routine blood draw. In a New England Journal of Medicine study of more than 10,000 patients, the test demonstrated 83.1% sensitivity for colorectal cancer and 89.6% specificity. It is the only FDA-approved blood-based CRC screening tool included in both American Cancer Society and National Comprehensive Cancer Network guidelines.
GH shares surged as much as 10% Wednesday to trade at their highest level in more than five years. The stock has gained about 61% year to date and more than tripled over the past 12 months, outpacing the S&P 500. BTIG called the UnitedHealth decision a "huge" derisking event for Guardant's screening business and raised its price target to $190 from $150, implying about 27% upside from Tuesday's close.
UnitedHealth Group, the largest US commercial insurer with about 40 million members across employer plans, Medicare Advantage and supplemental Medicare coverage, will apply the updated policy starting Aug. 1. The coverage applies to eligible policyholders aged 45 or older at average risk of colorectal cancer — a population that has seen rising incidence rates in recent years. Colorectal cancer is now the leading cause of cancer death for Americans under 50, according to Scientific American.
The decision pressures other major insurers including Anthem, Aetna and Cigna to follow suit, analysts said. Citi described the move as "another positive catalyst" for Guardant, noting it "unlocks a new cohort of volumes and should drive significant average selling price benefits." The coverage arrived roughly one to two years ahead of BTIG's expectations, the firm said.
Guardant's Shield test competes with Exact Sciences Corp.'s Cologuard, a stool-based DNA test, and traditional colonoscopy, the gold standard. Cologuard generated about $2.3 billion in revenue for Exact Sciences in 2025, according to company filings. Shield's blood-based approach eliminates the need for stool collection or bowel preparation, potentially expanding the addressable screening population beyond the roughly 60% of eligible Americans who are currently up to date with CRC screening.
GH shares, trading at elevated multiples after the year's rally, still have room to run if additional commercial insurers adopt similar coverage policies, analysts said. The company's screening business now has a clearer path to revenue growth, with the UnitedHealth decision serving as a potential template for national coverage determinations.
This article is for informational purposes only and does not constitute investment advice.
